CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
The purpose of this study (Part 1 and Part 2) is to evaluate the relative vaccine efficacy (rVE), safety, reactogenicity, and immunogenicity of mRNA-...
Phase 3
Austin, Texas, United States of America and 217 other locations
This is a phase 2 double-blind, randomized study of PBI-0451(Pomotrelvir) in nonhospitalized symptomatic adults with COVID-19. PBI--...
Phase 2
Austin, Texas, United States of America and 54 other locations
(SARS-CoV2) vaccine tablet VXA-CoV2-3.1 compared to a currently recommended vaccine for the prevention of symptomatic Coronavirus Disease 2019 (COVID...
Phase 2
Austin, Texas, United States and 144 other locations
known SARS-CoV-2 variants of concern for pre-exposure prophylaxis of COVID-19.The aim of the Phase I/III study (Parent Study) will -...
Phase 2, Phase 3
Austin, Texas, United States and 214 other locations
be tolerated for treatment of pregnant women with mild or moderate COVID-19 compared to non-pregnant women with mild or moderate CO-...
Phase 1
Austin, Texas, United States and 32 other locations
The purpose of this study is to evaluate the safety, reactogenicity and immune responses of the severe acute respiratory syndrome coronavirus 2 (SARS...
Phase 1
Austin, Texas, United States and 3 other locations
The purpose of this study is to understand the safety and effects of a combined influenza and COVID-19 vaccine. This combined vacci-...
Phase 3
Austin, Texas, United States and 162 other locations
This is a Phase 2/3, randomized, double-blind study to evaluate the safety and immunogenicity of different booster dose levels of the monovalent seve...
Phase 2, Phase 3
Austin, Texas, United States of America and 49 other locations
for teenagers. The booster targets a particular variant of COVID-19, Omicron XBB.1.5. The main focus is on safety: researchers want-...
Phase 3
Austin, Texas, United States of America and 19 other locations
This study will evaluate the safety and immunogenicity of the mRNA-1273.214 vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)...
Phase 3
Austin, Texas, United States and 69 other locations
Clinical trials
Research sites
Resources
Legal